Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure
pharmafile | April 26, 2019 | News story | Medical Communications, Sales and Marketing | Cancer, Eli Lilly, Lartruvo, pharma, soft tissue sarcoma
Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from the market as a treatment for advanced soft tissue sarcoma (STS) due to the drug’s failure to adequately address the condition in Phase 3 trials.
Lartruvo failed to meet its primary endpoint of improvement in overall survival in the ANNOUNCE trial earlier this year.
In order to make sure that patients already using the drug do not lose access once it is no longer available on the market, Lilly has announced it is working to launch a programme to minimise interruption to their ongoing treatment, provided they do so in consultation with a physician and have been made aware of the risks of the medicine.
However, no new patients will be able to begin treatment with the drug in this indication once it has been withdrawn outside of ongoing clinical trials.
“Lilly wants to ensure that patients and physicians feel supported during this important time,” said Anne White, President at Lilly Oncology. “Advanced soft tissue sarcoma is a rare and difficult-to-treat cancer. Establishing this programme will give patients who are currently taking Lartruvo the opportunity to continue their treatment programme uninterrupted.”
Matt Fellows
Related Content
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …